Rafael Holdings Inc RFL

Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. It holds a majority equity interest in LipoMedix Pharmaceuticals Ltd. (a clinical-stage pharmaceutical company), Barer Institute Inc. (a preclinical cancer metabolism research operation), and a majority interest in Cornerstone Pharmaceuticals, Inc. (a cancer metabolism-based therapeutics company). It holds a majority interest in Rafael Medical Devices, LLC., an orthopedic-focused medical device company, and a majority interest in Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their cannabis offerings enabling them to bring to market predictable versions by utilizing Day Three's pharmaceutical-grade technology and innovation like Unlokt. Its investments include Cyclo Therapeutics Inc. (developing Trappsol Cyclo). It holds a portion of a commercial building in Israel.

NYSE:RFL - Post by User

Rafael Holdings Inc

Bullboard Posts

Next >>

Post by AviseAnalyticson Nov 29, 2021 6:49am

275 Views

Post# 34174879

5 REASONS WHY RAFAEL HOLDINGS IS A RISKY INVESTMENT!

$RFL

Rafael Holdings Inc, whose subsidiaries include Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd, has announced a realignment of the management team.

The move comes on the heels of the Company’s subsidiary Rafael Pharmaceuticals announcing that its lead candidate devimistat (CPI-613) failed to achieve its primary objective of overall survival (OS) in a crucial Phase III trial and another trial in acute myeloid leukemia (AML) was halted due to lack of efficacy.

We take a look at the Company's pipeline and its prospects in our article today.

Read on to know more:

https://www.aviseanalytics.com/5-reasons-why-rafael-holdings-is-a-risky-investment/

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant